花旗发表研究报告指,巨子生物(02367.HK) 2025年净利润下跌7%,符合公司去年12月指引的中高个位数跌幅,并与该行预期一致。期内收入持平,同样符合预期,线上直销业务表现较佳,抵销了分销业务的疲软。集团管理层目标2026年收入增长10%,在考虑到利润率收缩下,净利润目标为增长或持平,该行认为这较市场悲观预期为佳。报告称,巨子生物去年下半年部分业务表现超出预期,包括天猫及抖音销售跌幅小于预期...
Source Link花旗发表研究报告指,巨子生物(02367.HK) 2025年净利润下跌7%,符合公司去年12月指引的中高个位数跌幅,并与该行预期一致。期内收入持平,同样符合预期,线上直销业务表现较佳,抵销了分销业务的疲软。集团管理层目标2026年收入增长10%,在考虑到利润率收缩下,净利润目标为增长或持平,该行认为这较市场悲观预期为佳。报告称,巨子生物去年下半年部分业务表现超出预期,包括天猫及抖音销售跌幅小于预期...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.